Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026)

Bicara Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 37508000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 33.45% year-over-year to 37508000.0 in Q1 2026; TTM through Mar 2026 was 116236000.0, a 31.68% decrease from a year earlier, with the FY2025 full-year figure at 106834000.0, down 42.92% from the prior year.
• Cash from Operations retreated to 37508000.0 in Q1 2026 per BCAX's latest filing, from 23886000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 8036000.0 in Q4 2023 and bottomed at 37508000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 24740000.0 (2025), against an average of 22712900.0.
• Across the five-year window, Cash from Operations sank 273.72% in 2024 and rose 20.46% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 8036000.0 in 2023, then sank by 273.72% to 30032000.0 in 2024, then climbed by 20.46% to 23886000.0 in 2025, then plunged by 57.03% to 37508000.0 in 2026.
• Per Business Quant, the three latest BCAX Cash from Operations figures stand at 37508000.0 (Q1 2026), 23886000.0 (Q4 2025), and 29248000.0 (Q3 2025).